GSK gets Boostrix approval for adults over 65

GlaxoSmithKline has gained FDA approval for its tetanus, diphtheria and whooping cough vaccine Boostrix in adults 65 and older. It's the first vaccine that protects older adults from all three diseases with a single shot. With the expanded indication, the vaccine can now be given to people over the age of 10.

"Although many people may have been vaccinated against whooping cough as children, immunity can wear off over time," explained GSK VP of Medical Affairs Leonard Friedland. "Adults, including those age 65 and older, should speak with their healthcare providers to make sure their vaccinations are up to date and to discuss the Centers for Disease Control and Prevention's recommendations for preventing tetanus, diphtheria and pertussis."

Whooping cough cases are on the rise due in part to some parents refusing to get their children vaccinated. Michigan, Ohio, New York and Pennsylvania have all reported a rise in cases of the disease, and California declared a whooping cough epidemic in 2010.

- here's GSK's release
- read more from UPI

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.